| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print April 10, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




From the Department of Medicine-Nephrology,* Baylor College of Medicine, Houston, Texas; the Department of Medicine,
The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong; and the Department of Pathology,
Methodist Hospital, Houston, Texas
The recent discovery of the angiotensin II (Ang II)-breakdown enzyme, angiotensin I converting enzyme (ACE) 2, suggests the importance of Ang II degradation in hypertension. The present study explored the signaling mechanism by which ACE2 is regulated under hypertensive conditions. Real-time PCR and immunohistochemistry showed that ACE2 mRNA and protein expression levels were high, whereas ACE expression levels were moderate in both normal kidney and heart. In contrast, patients with hypertension showed marked ACE up-regulation and ACE2 down-regulation in both hypertensive cardiopathy and, particularly, hypertensive nephropathy. The inhibition of ACE2 expression was shown to be associated with ACE up-regulation and activation of extracellular regulated (ERK)1/2 and p38 mitogen-activated protein (MAP) kinases. In vitro, Ang II was able to up-regulate ACE and down-regulate ACE2 in human kidney tubular cells, which were blocked by an angiotensin II (AT)1 receptor antagonist (losartan), but not by an AT2 receptor blocker (PD123319). Furthermore, blockade of ERK1/2 or p38 MAP kinases by either specific inhibitors or a dominant-negative adenovirus was able to abolish Ang II-induced ACE2 down-regulation in human kidney tubular cells. In conclusion, Ang II is able to up-regulate ACE and down-regulate ACE2 expression levels under hypertensive conditions both in vivo and in vitro. The AT1 receptor-mediated ERK/p38 MAP kinase signaling pathway may be a key mechanism by which Ang II down-regulates ACE2 expression, implicating an ACE/ACE2 imbalance in hypertensive cardiovascular and renal damage.
This article has been cited by other articles:
![]() |
M. Byku, H. Macarthur, and T. C. Westfall Inhibitory effects of angiotensin-(1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed Am J Physiol Heart Circ Physiol, February 1, 2010; 298(2): H457 - H465. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iizuka, A. Kusunoki, T. Machida, and M. Hirafuji Angiotensin II reduces membranous angiotensin-converting enzyme 2 in pressurized human aortic endothelial cells Journal of Renin-Angiotensin-Aldosterone System, December 1, 2009; 10(4): 210 - 215. [Abstract] [PDF] |
||||
![]() |
R. Zhang, Y. Wu, M. Zhao, C. Liu, L. Zhou, S. Shen, S. Liao, K. Yang, Q. Li, and H. Wan Role of HIF-1{alpha} in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2009; 297(4): L631 - L640. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Ferreira, V. Shenoy, Y. Yamazato, S. Sriramula, J. Francis, L. Yuan, R. K. Castellano, D. A. Ostrov, S. P. Oh, M. J. Katovich, et al. Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1048 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Gallagher, C. M. Ferrario, and E. A. Tallant Regulation of ACE2 in cardiac myocytes and fibroblasts Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2373 - H2379. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |